BEVACIZUMAB

Brand name:

• Mvasi®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Amgen Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Non-small cell lung cancer (NSCLC)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (Minor Submission)

Comment:

--

Other PBAC consideration:

• BEVACIZUMAB

Submission received for:

March 2021 PBAC meeting

Opportunity for consumer comment:

Open 23/12/2020 and close 10/02/2021 (see PBS Website)

PBAC meeting:

Held on 10/03/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

18/12/2020

Lodgement of required documentation:

15/01/2021

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 01/02/2021

Status:

Finalised

Government processes:

Commenced on 13/04/2021

Medicine listed on the PBS:

01/06/2021 (see PBS schedule)